Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEC53856 in Non-dialysis Renal Anemia
NCT04925661Phase 1Completed
- Sponsor
- Sunshine Lake Pharma
- Start
- Nov 2021
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HEC53856 in anemia of chronic kidney disease (3 arms), sponsored by Sunshine Lake Pharma. Primary endpoint: Incidence of Adverse Events at 12 weeks. Started Nov 2021; status: completed.
02
Drugs
HEC53856
03
Conditions
anemia of chronic kidney disease
Beyond the preview
Go deeper on NCT04925661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04925661.